Sets up a state-of-the-art microbial facility, expands mammalian facility
Syngene International has announced the expansion of its biomanufacturing capacity. The company has set up and commissioned a new microbial cGMP facility and has also expanded the capacity of its mammalian cell manufacturing facility to extend end-to-end Chemistry, Manufacturing and Control (CMC) development solutions for its global clients. Both facilities are located at its Biocon Park campus in Bengaluru, India.
The new microbial facility has two fermenters of 200 litres and 500 litres capacity. The microbial facility will provide further integration opportunities with the company’s existing discovery and development capabilities and extend service offerings in the space of GMP manufacturing of plasmid DNA and mRNA. In addition to this, another 2000L single-use bioreactor will be added to the US FDA and EMA compliant mammalian manufacturing facility. This is expected to strengthen Syngene’s service offerings for commercial supply. The expansion is building on Syngene’s existing biopharmaceuticals manufacturing capabilities and is aligned with its strategic focus on biologics as one of its future growth drivers.
Jonathan Hunt, MD and CEO, Syngene International said “The recent investments have increased our production capabilities for bulk drug substance to meet the growing requirements from our expanding client base for end-to-end cGMP clinical and commercial manufacturing.
The use of digitalisation and automation tools like electronic quality records and digital signatures will not only help avoid the risk of human errors but also decrease operational costs and improve time-to-market. Both the facilities are supported by proven processes for efficient, scalable, customised and regulatory-compliant commercial manufacturing.”
